

The Ventana Anti-Obesity Chewing Gum enables private investors to benefit from a biotechnological breakthrough addressing the scourge of the modern world: Obesity!

Ventana Biotech is a drug target acquisition and development company, specializing in developing an Anti-Obesity Chewing Gum that can regulate the user's appetite.

Profit potential from epidemic growth in obesity and the illnesses directly related to this.

World class management, an accomplished scientific team and a truly unique product.

Upon successful marketing, the potential income to Ventana has been estimated at \$ 2.9 billion.

WHO has estimated that the direct cost from obesity has exceeded \$ 100 billion, and the indirect cost from obesity-related illnesses an additional \$ 47.6 billion.



"We evaluate that the active ingredient in a product such as the Anti-Obesity Chewing Gum will be able to reduce appetite by as much as 15 - 25 %."

Prof. Gupta, Bangalore

"Ventana Biotech has focused its R&D efforts on targeted personalized medicines. By launching an Anti-Obesity Chewing Gum, the usual adversity against the common kind of medicine can be overcome.

By using an Anti-Obesity Chewing Gum, people who would not otherwise be medicated for their obesity can be reached. This is extremely important as many obese people do not see themselves as being in need of treatment. As obesity is becoming the biggest health-cost to society, it is more important than ever to be able to reach this target group. Our Anti-Obesity Chewing Gum does just that."